







# Atopic Dermatitis and Prurigo Nodularis Are Distinct Skin Diseases With Shared Characteristics

	ATOPIC DERMATITIS	PRURIGO NODULARIS
PATIENTS	 <ul style="list-style-type: none"> <li>Majority of patients develop AD by 5 years of age<sup>1</sup></li> </ul>	 <ul style="list-style-type: none"> <li>Majority of patients develop PN between ages 51–65 years and/or are female<sup>2–4</sup></li> </ul>
FEATURES	 <ul style="list-style-type: none"> <li>Characterized by intense, chronic pruritus and recurrent eczematous lesions which show periods of clearance and flares<sup>5–8</sup></li> <li>Heterogenous presentation across age groups with wide spectrum of clinical features<sup>6,7</sup></li> </ul>	 <ul style="list-style-type: none"> <li>Characterized by bilaterally distributed lesions that present as intensely pruritic dome-shaped nodules, papules, or plaques<sup>9–11</sup></li> </ul>
PATHOPHYSIOLOGY	 <ul style="list-style-type: none"> <li>Genetics, type 2 inflammation, and environmental factors contribute to the development of AD however the exact cause is not yet elucidated<sup>5–7</sup></li> <li>Epidermal barrier dysfunction is critical for the perpetuation of AD disease and the itch-scratch cycle<sup>12,13</sup></li> </ul>	 <ul style="list-style-type: none"> <li>Exact etiology of PN is not known, however disease is thought to result from neuroimmune dysregulation, leading to intense, chronic itch-scratch cycle and formation of fibrotic nodules<sup>4,14</sup></li> </ul>



Both diseases are characterized by chronic itch, skin lesions, and negatively impact QoL (e.g., loss of sleep)<sup>6,10</sup>

AD, atopic dermatitis; QoL, quality of life.

1. Silverberg NB, Durán-McKinster C. *Dermatol Clin*. 2017;35(3):351. 2. Mullins TB, et al. *StatPearls* [Internet]. 2022. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK459204/>. Accessed June 2023. 3. Whang KA, et al. *J Allergy Clin Immunol Pract*. 2020;8(9):3240–3241. 4. Williams KA, et al. *Expert Rev Clin Pharmacol*. 2021;14(1):67–77. 5. Haddad EB, et al. *Dermatol Ther* (Heidelb). 2022;12:1501–1533. 6. Weidinger S, et al. *Nat Rev Dis Primers*. 2018;4:1. 7. Girolomoni G, et al. *Ther Adv in Chron Dis*. 2021;9:303. 8. Sidbury R, et al. *J Am Acad Dermatol*. 2014;71:1218–1233. 9. Misery L. *Br J Dermatol*. 2022;187:464–471. 10. Pereira MP, et al. *J Eur Acad Dermatol Venereol*. 2018;32:1059–1065. 11. Kwon CD, et al. *Medicines* (Basel). 2019;6(4):97. 12. Beck LA, et al. *J Invest Dermatol Innovations*. 2022;2(5):100131. 13. Folster-Host R, et al. *Biology*. 2021;10:1008. 14. Kwatra SG. *New Engl J Med*. 2020;382:757–758.

STAY IN THE KNOW ABOUT THE EVOLVING SCIENCE OF TYPE 2 INFLAMMATION

For more information visit [ADVENTprogram.com](http://ADVENTprogram.com)



ADVENT is a medical education non-promotional program for healthcare professionals organized by Sanofi and Regeneron.

© 2023 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2302776 v1 06/2023

sanofi | REGENERON®

*“ADVENT is a breakthrough educational program bringing together different specialties treating patients with type 2 inflammatory diseases.”*  
Prof. Thomas Bieber, Dermatologist, Germany

## What is the ADVENT program?

ADVENT is a global medical education program that shares the latest evidence on diseases with underlying type 2 inflammation

### Areas covered include:



#### DERMATOLOGY

- Atopic dermatitis
- Prurigo nodularis
- Chronic spontaneous urticaria



#### RESPIRATORY

- Asthma
- Chronic rhinosinusitis with nasal polyps



#### GASTROENTEROLOGY

- Eosinophilic esophagitis

### The goals of the platform are:



Improve patient care



Facilitate cross-specialty knowledge sharing



Explore multidisciplinary implications of underlying type 2 inflammation



Reduce the burden of diseases driven by underlying type 2 inflammation

## What does ADVENT have to offer?

### ADVENT materials were developed with:



More than **120 experts** from more than **15 countries**



Specialists in **allergy, dermatology, gastroenterology, otolaryngology** and **respiratory** medicine

**STAY IN THE KNOW ABOUT THE EVOLVING SCIENCE OF TYPE 2 INFLAMMATION**

For more information visit [ADVENTprogram.com](https://ADVENTprogram.com)

### The ADVENT program provides:



On-demand events



Expert presentations



Self-guided educational resources



Expert interviews



Infographics



Activities adapted for local needs and languages

